TrialJournal of the National Cancer Institute2024

Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.

Rebecca Dent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.